Neoadjuvant Chemotherapy Combined With Finotonlimab in the Treatment of Locally Advanced Hypopharyngeal Carcinoma

This study investigates a combination treatment for locally advanced cancer of the hypopharynx (the lower part of the throat). It combines an immune checkpoint drug called finotonlimab with chemotherapy (nab-paclitaxel) given before surgery, to see if it improves outcomes while preserving the ability to speak and swallow. **You may be eligible if...** - You are between 18 and 75 years old - You have been newly diagnosed with stage III or IVA hypopharyngeal cancer and have not yet received treatment - Your tumor showed at least 50% shrinkage after the initial chemotherapy phase - You are in good general health (ECOG performance score 0–2) **You may NOT be eligible if...** - You are pregnant or breastfeeding - You are allergic to any of the study drugs - You have poorly controlled heart disease or other serious health conditions - You have a history of active autoimmune disease requiring systemic treatment - You have had another cancer at the same time or in the past Talk to your doctor to see if this trial is right for you.